TY - JOUR
KW - Adult
KW - Buprenorphine/therapeutic use
KW - Cocaine-Related Disorders/epidemiology
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Opiate Substitution Treatment/statistics & numerical data
KW - Opioid-Related Disorders/drug therapy
KW - Patient Compliance/statistics & numerical data
KW - Philadelphia
KW - Primary Health Care/methods
KW - Retrospective Studies
KW - Treatment Outcome
KW - Vulnerable Populations
AU - L. C. Weinstein
AU - Q. Iqbal
AU - A. Cunningham
AU - R. Debates
AU - G. Landistratis
AU - P. Doggett
AU - A. Silverio
A1 - 
AB - Objectives. To describe and report initial outcomes of a low-threshold, group-based primary care medication for opioid use disorder (OUD) program in a federally qualified health center.Methods. We performed a retrospective chart review of patients enrolled in the program from October 4, 2017, to October 3, 2018, in Philadelphia, Pennsylvania. The main outcome measure was time retained in treatment, defined as time from treatment initiation to unplanned treatment termination. Secondary outcomes were the relationships between treatment retention and cocaine use or housing status. We analyzed retention in treatment using Kaplan-Meier survival estimates.Results. The 3- and 6-month retention rates were 82% and 63%, respectively. The log-rank test showed no significant differences for comparisons between homeless versus not homeless (P = .25) and cocaine use versus no cocaine use (P = .12).Conclusions. The medication for OUD program engaged a large number of patients from marginalized groups. Three- and 6-month retention rates were comparable with those reported of other federally qualified health center populations.Public Health Implications. Integrating treatment of OUD into primary care shows promise for increasing access to and retention in medication for OUD services. The federally qualified health center payment structure supports the sustainability of the group visit model.
AD - Lara Carson Weinstein, Qais Iqbal, Amy Cunningham, and Alexis Silverio are with the Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA. Robin Debates, Greg Landistratis, and Patrick Doggett are with Project HOME Health Services, Philadelphia.; Lara Carson Weinstein, Qais Iqbal, Amy Cunningham, and Alexis Silverio are with the Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA. Robin Debates, Greg Landistratis, and Patrick Doggett are with Project HOME Health Services, Philadelphia.; Lara Carson Weinstein, Qais Iqbal, Amy Cunningham, and Alexis Silverio are with the Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA. Robin Debates, Greg Landistratis, and Patrick Doggett are with Project HOME Health Services, Philadelphia.; Lara Carson Weinstein, Qais Iqbal, Amy Cunningham, and Alexis Silverio are with the Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA. Robin Debates, Greg Landistratis, and Patrick Doggett are with Project HOME Health Services, Philadelphia.; Lara Carson Weinstein, Qais Iqbal, Amy Cunningham, and Alexis Silverio are with the Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA. Robin Debates, Greg Landistratis, and Patrick Doggett are with Project HOME Health Services, Philadelphia.; Lara Carson Weinstein, Qais Iqbal, Amy Cunningham, and Alexis Silverio are with the Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA. Robin Debates, Greg Landistratis, and Patrick Doggett are with Project HOME Health Services, Philadelphia.; Lara Carson Weinstein, Qais Iqbal, Amy Cunningham, and Alexis Silverio are with the Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA. Robin Debates, Greg Landistratis, and Patrick Doggett are with Project HOME Health Services, Philadelphia.
BT - American Journal of Public Health
C5 - Opioids & Substance Use; Financing & Sustainability; Healthcare Disparities; Healthcare Policy
CP - 4
DO - 10.2105/AJPH.2019.305525
IS - 4
JF - American Journal of Public Health
LA - eng
M1 - Journal Article
N2 - Objectives. To describe and report initial outcomes of a low-threshold, group-based primary care medication for opioid use disorder (OUD) program in a federally qualified health center.Methods. We performed a retrospective chart review of patients enrolled in the program from October 4, 2017, to October 3, 2018, in Philadelphia, Pennsylvania. The main outcome measure was time retained in treatment, defined as time from treatment initiation to unplanned treatment termination. Secondary outcomes were the relationships between treatment retention and cocaine use or housing status. We analyzed retention in treatment using Kaplan-Meier survival estimates.Results. The 3- and 6-month retention rates were 82% and 63%, respectively. The log-rank test showed no significant differences for comparisons between homeless versus not homeless (P = .25) and cocaine use versus no cocaine use (P = .12).Conclusions. The medication for OUD program engaged a large number of patients from marginalized groups. Three- and 6-month retention rates were comparable with those reported of other federally qualified health center populations.Public Health Implications. Integrating treatment of OUD into primary care shows promise for increasing access to and retention in medication for OUD services. The federally qualified health center payment structure supports the sustainability of the group visit model.
PY - 2020
SN - 1541-0048; 0090-0036; 0090-0036
SP - 580
EP - 586
EP - 
T1 - Retention of Patients With Multiple Vulnerabilities in a Federally Qualified Health Center Buprenorphine Program: Pennsylvania, 2017-2018
T2 - American Journal of Public Health
TI - Retention of Patients With Multiple Vulnerabilities in a Federally Qualified Health Center Buprenorphine Program: Pennsylvania, 2017-2018
U1 - Opioids & Substance Use; Financing & Sustainability; Healthcare Disparities; Healthcare Policy
U2 - 32078355
U3 - 10.2105/AJPH.2019.305525
VL - 110
VO - 1541-0048; 0090-0036; 0090-0036
Y1 - 2020
Y2 - Apr
ER -